Literature DB >> 17390183

Gastrectomy as a remedial operation for failed fundoplication.

Valerie A Williams1, Thomas J Watson, Oliver Gellersen, Sebastian Feuerlein, Daniela Molena, Lelan F Sillin, Carolyn Jones, Jeffrey H Peters.   

Abstract

The decision for, and choice of, a remedial antireflux procedure after a failed fundoplication is a challenging clinical problem. Success depends upon many factors including the primary symptom responsible for failure, the severity of underlying anatomic and physiologic defects, and the number and type of previous remedial attempts. Satisfactory outcomes after reoperative fundoplication have been reported to be as low as 50%. Consequently, the ideal treatment option is not clear. The purpose of this study was to evaluate the outcome of gastrectomy as a remedial antireflux procedure for patients with a failed fundoplication. The study population consisted of 37 patients who underwent either gastrectomy (n = 12) with Roux-en-Y reconstruction or refundoplication (n = 25) between 1997-2005. Average age, M/F ratio, and preoperative BMI were not significantly different between the two groups. Outcome measures included perioperative morbidity, relief of primary and secondary symptoms, and the patients' overall assessment of outcome. Mean follow up was 3.5 and 3.3 years in the gastrectomy and refundoplication groups, respectively (p = 0.43). Gastrectomy patients had a higher prevalence of endoscopic complications of GERD (58% vs 4%, p = 0.006) and of multiple prior fundoplications than those having refundoplication (75% vs 24%, p = 0.004). Mean symptom severity scores were improved significantly by both gastrectomy and refundoplication, but were not significantly different from each other. Complete relief of the primary symptom was significantly greater after gastrectomy (89% vs 50%, p = 0.044). Overall patient satisfaction was similar in both groups (p = 0.22). In-hospital morbidity was higher after gastrectomy than after refundoplication (67% vs 20%, p = 0.007) and new onset dumping developed in two gastrectomy patients. In select patients with severe gastroesophageal reflux disease (GERD) and multiple previous fundoplications, primary symptom resolution occurs significantly more often after gastrectomy than after repeat fundoplication. Gastrectomy, however, is associated with higher morbidity. Gastrectomy is an acceptable treatment option for recurrent symptoms particularly when another attempt at fundoplication is ill advised, such as in the setting of multiple prior fundoplications or failed Collis gastroplasty.

Entities:  

Mesh:

Year:  2007        PMID: 17390183     DOI: 10.1007/s11605-006-0048-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  20 in total

1.  Esophageal reconstruction for benign disease: early morbidity, mortality, and functional results.

Authors:  M M Young; C Deschamps; V F Trastek; M S Allen; D L Miller; C D Schleck; P C Pairolero
Journal:  Ann Thorac Surg       Date:  2000-11       Impact factor: 4.330

2.  Regression of intestinal metaplasia to cardiac or fundic mucosa in patients with Barrett's esophagus submitted to vagotomy, partial gastrectomy and duodenal diversion. A prospective study of 78 patients with more than 5 years of follow up.

Authors:  Attila Csendes; Italo Bragheto; Patricio Burdiles; Gladys Smok; Ana Henriquez; Francisco Parada
Journal:  Surgery       Date:  2006-01       Impact factor: 3.982

Review 3.  Roux-en-Y long limb diversion as the first option for patients who have Barrett's esophagus.

Authors:  Attila Csendes; Italo Braghetto; Patricio Burdiles; Owen Korn
Journal:  Chest Surg Clin N Am       Date:  2002-02

4.  Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.

Authors:  L Lundell; P Miettinen; H E Myrvold; S A Pedersen; B Liedman; J G Hatlebakk; R Julkonen; K Levander; J Carlsson; M Lamm; I Wiklund
Journal:  J Am Coll Surg       Date:  2001-02       Impact factor: 6.113

5.  Treatment of severe peptic esophageal stricture with Roux-en-Y partial gastrectomy, vagotomy, and endoscopic dilation. A follow-up study.

Authors:  J A Salo; K V Ala-Kulju; L O Heikkinen; E O Kivilaakso
Journal:  J Thorac Cardiovasc Surg       Date:  1991-04       Impact factor: 5.209

6.  Surgical management after failed antireflux operations.

Authors:  D B Skinner
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  Long-term results after reoperation for failed antireflux procedures.

Authors:  C Deschamps; V F Trastek; M S Allen; P C Pairolero; J O Johnson; D R Larson
Journal:  J Thorac Cardiovasc Surg       Date:  1997-03       Impact factor: 5.209

8.  Results of gastric bypass plus resection of the distal excluded gastric segment in patients with morbid obesity.

Authors:  Attila Csendes; Patricio Burdiles; Karin Papapietro; Juan Carlos Diaz; Fernando Maluenda; Ana Burgos; Jorge Rojas
Journal:  J Gastrointest Surg       Date:  2005-01       Impact factor: 3.452

9.  Esophageal replacement for end-stage benign esophageal disease.

Authors:  T J Watson; T R DeMeester; W K Kauer; J H Peters; J A Hagen
Journal:  J Thorac Cardiovasc Surg       Date:  1998-06       Impact factor: 5.209

10.  Late laparoscopic reoperation of failed antireflux procedures.

Authors:  Julio C U Coelho; Carolina G Gonçalves; Christiano M P Claus; Paulo C Andrigueto; Matheus N Ribeiro
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2004-06       Impact factor: 1.719

View more
  16 in total

1.  Outcomes after esophagectomy in patients with prior antireflux or hiatal hernia surgery.

Authors:  Andrew C Chang; Julia S Lee; Konrad T Sawicki; Allan Pickens; Mark B Orringer
Journal:  Ann Thorac Surg       Date:  2010-04       Impact factor: 4.330

2.  Roux-en-Y reconstruction for failed fundoplication.

Authors:  Konstantinos I Makris; Tommy Lee; Sumeet K Mittal
Journal:  J Gastrointest Surg       Date:  2009-09-02       Impact factor: 3.452

3.  Efficacy and feasibility of laparoscopic redo fundoplication.

Authors:  Lokesh Bathla; Andras Legner; Kazuto Tsuboi; Sumeet Mittal
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

Review 4.  Pathophysiology of gastroesophageal reflux disease: how an antireflux procedure works (or does not work).

Authors:  Fernando A M Herbella; Francisco Schlottmann; Marco G Patti
Journal:  Updates Surg       Date:  2018-07-23

5.  Evaluation of gastrectomy in patients with delayed gastric emptying after antireflux surgery or large hiatal hernia repair.

Authors:  Arja Gerritsen; Edgar J B Furnée; Hein G Gooszen; Maurits Wondergem; Eric J Hazebroek
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

6.  Perioperative outcomes of surgical procedures for symptomatic fundoplication failure: a retrospective case-control study.

Authors:  Sandeepa Musunuru; Jon C Gould
Journal:  Surg Endosc       Date:  2011-11-04       Impact factor: 4.584

7.  Roux-en-Y reconstruction is superior to redo fundoplication in a subset of patients with failed antireflux surgery.

Authors:  Sumeet K Mittal; András Légner; Kazuto Tsuboi; Arpad Juhasz; Lokesh Bathla; Tommy H Lee
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

8.  Minimally invasive Roux-en-Y reconstruction as a salvage operation after failed nissen fundoplication.

Authors:  Joshua P Landreneau; Andrew T Strong; Matthew D Kroh; John H Rodriguez; Kevin El-Hayek
Journal:  Surg Endosc       Date:  2019-07-25       Impact factor: 4.584

9.  Long-term outcomes of reintervention for failed fundoplication: redo fundoplication versus Roux-en-Y reconstruction.

Authors:  Se Ryung Yamamoto; Masato Hoshino; Kalyana C Nandipati; Tommy H Lee; Sumeet K Mittal
Journal:  Surg Endosc       Date:  2013-10-03       Impact factor: 4.584

Review 10.  Surgical reintervention after failed antireflux surgery: a systematic review of the literature.

Authors:  Edgar J B Furnée; Werner A Draaisma; Ivo A M J Broeders; Hein G Gooszen
Journal:  J Gastrointest Surg       Date:  2009-04-04       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.